Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21881632 | 1.00 | AGTR2 (0.74) | AGTR2AGTR1 | |
| SCHEMBL21881131 | 1.00 | AGTR2 (0.74) | AGTR2AGTR1 | |
| SCHEMBL21881125 | 1.00 | AGTR2 (0.74) | AGTR2AGTR1 | |
| SCHEMBL21881127 | 1.00 | AGTR2 (0.74) | AGTR2AGTR1 | |
| SCHEMBL21881126 | 1.00 | AGTR2 (0.74) | AGTR2AGTR1 | |
| SCHEMBL23315293 | 0.92 | AGTR2 (0.77) | AGTR2AGTR1 | |
| SCHEMBL21881546 | 0.92 | AGTR2 (0.77) | AGTR2AGTR1 | |
| SCHEMBL21881231 | 0.92 | AGTR2 (0.77) | AGTR2AGTR1 | |
| SCHEMBL23315304 | 0.92 | AGTR2 (0.77) | AGTR2AGTR1 | |
| SCHEMBL21881267 | 0.92 | AGTR2 (0.77) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-06-01 | — | — | US | disclosed |
| EP-3620454-B1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| US-20200102275-A1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102275-A1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | AGTR2, AGTR1, HCAR2 | AGTR2 1/4885AGTR1 2/4885 |
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | AGTR2, AGTR1, HCAR2 | AGTR2 1/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.